Yth12.5 Biosimilar – Anti-CD3E mAb – Research Grade from ProteoGenix; catalogue PX-TA1071; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Yth12.5 Biosimilar is a novel antibody that has been developed as a biosimilar version of Anti-CD3E monoclonal antibody (mAb). This biosimilar is specifically designed for research purposes and has shown promising results in preclinical studies. In this article, we will discuss the structure, activity, and potential applications of Yth12.5 Biosimilar as a therapeutic target.
Yth12.5 Biosimilar is a recombinant humanized IgG1 monoclonal antibody that is composed of two heavy chains and two light chains. It has a molecular weight of approximately 150 kDa and is produced using Chinese hamster ovary (CHO) cells. The antibody has a variable region that specifically binds to the CD3E antigen and a constant region that mediates effector functions.
The primary activity of Yth12.5 Biosimilar is the specific binding to the CD3E antigen. CD3E is a transmembrane protein that is expressed on the surface of T cells. It plays a crucial role in the activation and proliferation of T cells. By binding to CD3E, Yth12.5 Biosimilar can modulate the function of T cells and regulate the immune response.
In addition to its binding activity, Yth12.5 Biosimilar also has effector functions that can mediate the destruction of target cells. These effector functions include antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). These mechanisms can be utilized for the treatment of diseases where abnormal or overactive T cells are involved, such as autoimmune disorders and certain types of cancer.
Yth12.5 Biosimilar has a wide range of potential applications due to its ability to modulate the immune response. One of the main applications of this biosimilar is in the treatment of autoimmune diseases. By targeting and regulating the function of T cells, Yth12.5 Biosimilar can help to reduce the excessive immune response that is responsible for these diseases.
Another potential application of Yth12.5 Biosimilar is in the treatment of certain types of cancer. T cells play a crucial role in the body’s immune response against cancer cells. By targeting CD3E, Yth12.5 Biosimilar can enhance the activity of T cells and promote the destruction of cancer cells. This can be particularly beneficial in combination with other cancer treatments, such as chemotherapy or immunotherapy.
Furthermore, Yth12.5 Biosimilar can also be used in research studies to better understand the role of CD3E in various diseases and to develop new therapies targeting this antigen. Its high specificity and activity make it a valuable tool for studying the immune system and its dysregulation in different conditions.
In conclusion, Yth12.5 Biosimilar is a novel antibody that has been developed as a biosimilar version of Anti-CD3E mAb. Its structure, activity, and potential applications make it a promising therapeutic target for various diseases, particularly autoimmune disorders and cancer. Further studies and clinical trials are needed to fully assess the safety and efficacy of Yth12.5 Biosimilar, but initial results show great potential for this biosimilar in the field of immunotherapy.
Yth12.5 Biosimilar, Anti-CD3E mAb, biosimilar, antibody, therapeutic target, research, structure, activity, applications, autoimmune diseases, cancer, immunotherapy.
ProteoGenix catalogue number PX-TA1071. For research use only.
Target: Yth12.5 Biosimilar – Anti-CD3E mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: Mammalian cells; Purity: >85%; Buffer: PBS buffer PH7.5; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Yth12.5 Biosimilar – Anti-CD3E mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
